Filing Flows › Health Care › Shattuck Labs (STTK)
Shattuck Labs (STTK) earnings and revenue breakdown
Latest: Q3 2025 · 10-Q filed Nov 6, 2025 · Shattuck Labs (STTK) Q3 2025 earnings results →
Q3 2025 Revenue down 67% year over year to $1.0M
Shattuck Labs made $1.0M in Q3 2025 (-67% Y/Y). Operating margin n/m, net loss $10.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 6, 2025.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.0M in Q3 2025, down 67% year over year.
Operating costs exceeded revenue by $10.7M, an operating margin of -1071.6%. Total costs fell 44% while revenue fell 67%. The quarter ended with a net loss of $10.1M.
Operating cash flow was −$8.9M. Non-cash charges added back $917K of depreciation and $1.8M of share-based compensation. Working capital and other items used $1.6M. Capital expenditures of $71K exceeded it, leaving free cash flow of −$9.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2025 | 10-Q | Nov 6, 2025 | $1.0M | -67% | n/m | −$10.1M | −$8.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Shattuck Labs
We are a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific Death Receptor 3 (“DR3”) blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Our expertise in protein engineering and the development of novel tumor necrosis factor (“TNF”) receptor therapeutics come together in our lead program, SL-325, a potentially first-in-class DR3 blocking antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway than TL1A blocking antibodies.
In its own words, from its 10-K, filed Mar 5, 2026.
Shattuck Labs against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -67% against the peers' median +7%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| STTK Shattuck Labs | Q3 2025 | $1.0M | -67% | n/m |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Shattuck Labs 10-Q on SEC EDGAR · CIK 1680367 · Pharmaceutical Preparations
13F: who owns STTK and who is buying
More on STTK
History
Every quarter: Q3 2025 results